v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Product sales, net $ 2,425,738 $ 167,674 $ 5,350,445 $ 1,979,060
Cost of products sold 1,056,384 55,626 2,178,797 615,326
Gross profit 1,369,354 112,048 3,171,648 1,363,734
Selling, general and administrative expenses 4,011,672 3,155,630 6,760,969 5,875,123
Research and development expenses 14,834 108,170 35,760 215,650
Depreciation and amortization expense 215,420 21,138 231,864 54,457
Total operating expenses 4,241,926 3,284,938 7,028,593 6,145,230
Loss from operations (2,872,572) (3,172,890) (3,856,945) (4,781,496)
Interest expense (4,461) (4,062) (6,996) (8,159)
Gain on debt extinguishment-PPP 276,180 0 276,180 0
Loss before provision for income taxes and net of equity investments (2,600,853) (3,176,952) (3,587,761) (4,789,655)
Provision for income taxes (83) (1,250) (333) (1,500)
Loss before equity in net earnings (losses) of equity investments (2,600,936) (3,178,202) (3,588,094) (4,791,155)
Loss from China Joint Venture (95,857) 0 (94,556) 0
Net loss (2,696,793) (3,178,202) (3,682,650) (4,791,155)
Net loss attributable to noncontrolling interests (16,325) (11,738) (29,313) (24,476)
Net loss attributable to Milestone Scientific Inc. $ (2,680,468) $ (3,166,464) $ (3,653,337) $ (4,766,679)
Net loss per share applicable to common stockholders—        
Basic (in dollars per share) $ (0.04) $ (0.06) $ (0.05) $ (0.09)
Diluted (in dollars per share) $ (0.04) $ (0.06) $ (0.05) $ (0.09)
Weighted average shares outstanding and to be issued—        
Basic (in shares) 69,220,795 56,694,793 68,286,033 51,728,806
Diluted (in shares) 69,220,795 56,694,793 68,286,033 51,728,806

Source